Management of Gout in Patients with Colchicine-Resistant Flares

Introduction to Gout Management

• The American College of Rheumatology recommends starting allopurinol in patients with gout who are not responding to colchicine for flares, as it addresses the underlying cause of gout by reducing serum uric acid levels 1, 2

Understanding Gout Treatments

• Colchicine is used for acute flare management and prophylaxis, while allopurinol is a urate-lowering therapy (ULT) that reduces serum uric acid levels, serving different purposes in gout management 1, 3, 4

Indications for Allopurinol

• Allopurinol should be considered in patients with a definite diagnosis of gout, particularly those with recurrent flares, presence of tophi, urate arthropathy, and/or renal stones, as indicated by the European League Against Rheumatism 1, 5, 6

Initiation and Monitoring of Allopurinol

• The initial dose of allopurinol should be low (100 mg/day) and gradually increased until reaching the target serum uric acid level of <6 mg/dL, with monitoring to ensure target achievement, as recommended by the American College of Rheumatology 1, 4, 7

Prophylaxis During Allopurinol Initiation

• Concomitant anti-inflammatory prophylaxis, such as colchicine or NSAIDs, should be initiated when starting allopurinol to prevent paradoxical flares, with continuation for 3-6 months, as advised by the European League Against Rheumatism 1, 4

Special Patient Considerations

• For patients with renal impairment, lower doses (50-100 mg) of allopurinol should be used, with close monitoring, as recommended by the American College of Rheumatology 2